Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo, Teva OxyContin Generics Approved By FDA; Launch Dates Uncertain

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies' risk management programs will feature labeling, education, monitoring and intervention elements "consistent with" Purdue's program for the opioid.

You may also be interested in...



Endo's Generic OxyContin To Launch Following Patent Invalidation

D.C. federal appeals court upholds a ruling invalidating Purdue's patents due to inequitable conduct by the brand company. Endo says it holds 180-day exclusivity on three of four doses of oxycodone extended-release. Purdue plans to seek en banc review of the appellate panel's decision.

Endo's Generic OxyContin To Launch Following Patent Invalidation

D.C. federal appeals court upholds a ruling invalidating Purdue's patents due to inequitable conduct by the brand company. Endo says it holds 180-day exclusivity on three of four doses of oxycodone extended-release. Purdue plans to seek en banc review of the appellate panel's decision.

Lilly’s Symbyax Requires Prior Authorization Under Massachusetts Medicaid

Further drug list changes include prior authorization requirements for Schering-Plough’s Rebetol and Rebetron effective May 3. MassHealth will require prior authorization for J&J’s Duragesic and Purdue’s OxyContin beginning June 1.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel